JP2022526018A - 脳内への特異性が増強されたウイルス組成物 - Google Patents

脳内への特異性が増強されたウイルス組成物 Download PDF

Info

Publication number
JP2022526018A
JP2022526018A JP2021559829A JP2021559829A JP2022526018A JP 2022526018 A JP2022526018 A JP 2022526018A JP 2021559829 A JP2021559829 A JP 2021559829A JP 2021559829 A JP2021559829 A JP 2021559829A JP 2022526018 A JP2022526018 A JP 2022526018A
Authority
JP
Japan
Prior art keywords
aav capsid
aav
amino acid
cells
cases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021559829A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022526018A5 (cg-RX-API-DMAC7.html
Inventor
ヴィヴィアナ グラディナル,
スリプリヤ ラヴィンドラ クマール,
ベンジャミン デバーマン,
Original Assignee
カリフォルニア インスティテュート オブ テクノロジー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カリフォルニア インスティテュート オブ テクノロジー filed Critical カリフォルニア インスティテュート オブ テクノロジー
Publication of JP2022526018A publication Critical patent/JP2022526018A/ja
Publication of JP2022526018A5 publication Critical patent/JP2022526018A5/ja
Priority to JP2025065562A priority Critical patent/JP2025106514A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021559829A 2019-04-11 2020-04-10 脳内への特異性が増強されたウイルス組成物 Withdrawn JP2022526018A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025065562A JP2025106514A (ja) 2019-04-11 2025-04-11 脳内への特異性が増強されたウイルス組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962832826P 2019-04-11 2019-04-11
US62/832,826 2019-04-11
PCT/US2020/027708 WO2020210655A1 (en) 2019-04-11 2020-04-10 Virus compositions with enhanced specificity in the brain

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025065562A Division JP2025106514A (ja) 2019-04-11 2025-04-11 脳内への特異性が増強されたウイルス組成物

Publications (2)

Publication Number Publication Date
JP2022526018A true JP2022526018A (ja) 2022-05-20
JP2022526018A5 JP2022526018A5 (cg-RX-API-DMAC7.html) 2023-03-31

Family

ID=72751358

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021559829A Withdrawn JP2022526018A (ja) 2019-04-11 2020-04-10 脳内への特異性が増強されたウイルス組成物
JP2025065562A Pending JP2025106514A (ja) 2019-04-11 2025-04-11 脳内への特異性が増強されたウイルス組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025065562A Pending JP2025106514A (ja) 2019-04-11 2025-04-11 脳内への特異性が増強されたウイルス組成物

Country Status (9)

Country Link
US (1) US12644131B2 (cg-RX-API-DMAC7.html)
EP (1) EP3953371A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022526018A (cg-RX-API-DMAC7.html)
KR (1) KR20220007056A (cg-RX-API-DMAC7.html)
CN (1) CN114127090A (cg-RX-API-DMAC7.html)
AU (1) AU2020271108A1 (cg-RX-API-DMAC7.html)
CA (1) CA3136658A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202111249YA (cg-RX-API-DMAC7.html)
WO (1) WO2020210655A1 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021530218A (ja) 2018-07-11 2021-11-11 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. 血液脳関門を超える薬剤の送達のための方法および組成物
US11149256B2 (en) 2018-09-26 2021-10-19 California Institute Of Technology Adeno-associated virus compositions for targeted gene therapy
CN113166208B (zh) 2018-10-02 2024-11-22 沃雅戈治疗公司 重新定向aav衣壳的嗜性
EP4061947A4 (en) 2019-11-22 2024-04-24 California Institute of Technology METHODS FOR ROBUST CONTROL OF GENE EXPRESSION
CA3167290A1 (en) 2020-01-10 2021-07-15 The Brigham And Women's Hospital, Inc. Methods and compositions for delivery of immunotherapy agents across the blood-brain barrier to treat brain cancer
US12630842B2 (en) 2020-05-13 2026-05-19 Voyager Therapeutics, Inc. Redirection of tropism of AAV capsids
US20240067678A1 (en) * 2020-12-16 2024-02-29 Children's Medical Research Institute Adeno-associated virus capsids and vectors
JP2024500115A (ja) * 2020-12-18 2024-01-04 エイシー イミューン ソシエテ アノニム 抗体デリバリー
EP4322976A4 (en) * 2021-04-13 2025-06-25 Capsida, Inc. AAV COMPOSITIONS WITH HIGH EXPRESSION LEVELS IN THE BRAIN
WO2022221421A2 (en) * 2021-04-13 2022-10-20 Capsida, Inc. Aav compositions with high brain expression for treating mucopolysaccharidosis ii
US20250281643A1 (en) * 2021-04-13 2025-09-11 Capsida, Inc. Selected aav compositions having preferred brain enrichment
AU2022266615A1 (en) * 2021-04-27 2023-11-09 The General Hospital Corporation Aav capsids and uses thereof
EP4334332A4 (en) * 2021-05-04 2025-11-12 California Inst Of Techn VAA RECOMMENDANTS FOR ADMINISTRATION TO THE CENTRAL NERVOUS SYSTEM AND CEREBRAL VASCULATURE
US20240325568A1 (en) * 2021-07-20 2024-10-03 The Broad Institute, Inc. Engineered targeting compositions for endothelial cells of the central nervous system vasculature and methods of use thereof
KR20240095539A (ko) 2021-10-08 2024-06-25 디노 테라퓨틱스, 인코포레이티드 캡시드 변이체 및 이의 사용 방법
EP4426716A1 (en) 2021-11-02 2024-09-11 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
WO2023091934A1 (en) * 2021-11-16 2023-05-25 California Institute Of Technology Adeno-associated virus compositions having preferred heart and skeletal muscle enrichment
EP4473001A1 (en) * 2022-02-01 2024-12-11 The Broad Institute, Inc. Adeno-associated viral vectors and uses thereof
WO2023150632A2 (en) * 2022-02-02 2023-08-10 The Broad Institute, Inc. Targeting moieties promoting transduction of central nervous system cells and tissues and methods of use
CN119095867A (zh) * 2022-03-24 2024-12-06 卡西达公司 具有优选的脑富集的所选aav组合物
EP4532515A1 (en) * 2022-06-02 2025-04-09 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
KR20240014846A (ko) * 2022-07-26 2024-02-02 숙명여자대학교산학협력단 Aav2-anks1a 재조합 바이러스를 포함하는 알츠하이머 질병 치료용 조성물
AU2023364350A1 (en) 2022-10-19 2025-06-05 Affinia Therapeutics Inc. Recombinant aavs with improved tropism and specificity
CN116693633B (zh) * 2023-02-21 2023-12-22 广州派真生物技术有限公司 腺相关病毒突变体及其应用
JP2026509271A (ja) 2023-03-10 2026-03-17 ダイノ セラピューティクス,インコーポレーテッド カプシドポリペプチドおよびその使用方法
CN116983437B (zh) * 2023-07-26 2025-08-12 武汉大学中南医院 一种αOlig2的无损影像标记方法和产物及其用途
KR20260082361A (ko) 2023-08-31 2026-06-04 디노 테라퓨틱스, 인코포레이티드 캡시드 폴리펩타이드 및 이의 사용 방법
CN121219415A (zh) * 2023-10-19 2025-12-26 北京脑科学与类脑研究所 一种脑血管内皮细胞嵌合型启动子和重组表达载体及应用
WO2025155923A1 (en) * 2024-01-17 2025-07-24 The Broad Institute, Inc. Aav capsid modifications that enable improved cns-wide gene delivery through interactions with the transferrin receptor
TW202545971A (zh) 2024-02-08 2025-12-01 美商戴諾治療公司 殼體多肽及其使用方法
WO2025250454A1 (en) 2024-05-28 2025-12-04 University Of Rochester Adeno-associated viruses evolved to specifically target human glial progenitor cells in vivo
US20260061079A1 (en) * 2024-08-22 2026-03-05 Uniqure Biopharma B.V. BBB interacting capsids
WO2026064442A2 (en) 2024-09-18 2026-03-26 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
WO2026122963A1 (en) 2024-12-06 2026-06-11 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
CN121758572B (zh) * 2026-03-03 2026-06-09 凌意(杭州)生物科技有限公司 Aav9衣壳蛋白变体及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019506141A (ja) * 2015-12-11 2019-03-07 カリフォルニア インスティチュート オブ テクノロジー アデノ随伴ウイルス(aav)を誘導するための標的指向性ペプチド
JP2019509032A (ja) * 2016-02-16 2019-04-04 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 既存のヒト中和抗体に対して耐性である新規組換えアデノ随伴ウイルスカプシド

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1696036B1 (en) 1996-09-06 2010-04-21 The Trustees of The University of Pennsylvania Use of recombinant adeno-associated virus in the manufacture of a medicament for gene therapy via muscle cells
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
PL2900686T3 (pl) * 2012-09-28 2021-01-25 The University Of North Carolina At Chapel Hill Wektory aav ukierunkowane na oligodendrocyty
EP3564379A1 (en) 2013-09-13 2019-11-06 California Institute of Technology Selective recovery
MX2020001997A (es) * 2017-08-28 2020-07-20 Univ California Variantes de capside de virus adenoasociado y metodos de uso de estas.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019506141A (ja) * 2015-12-11 2019-03-07 カリフォルニア インスティチュート オブ テクノロジー アデノ随伴ウイルス(aav)を誘導するための標的指向性ペプチド
JP2019509032A (ja) * 2016-02-16 2019-04-04 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 既存のヒト中和抗体に対して耐性である新規組換えアデノ随伴ウイルスカプシド

Also Published As

Publication number Publication date
JP2025106514A (ja) 2025-07-15
EP3953371A4 (en) 2023-04-12
CN114127090A (zh) 2022-03-01
US20220220502A1 (en) 2022-07-14
US12644131B2 (en) 2026-06-02
AU2020271108A1 (en) 2021-11-11
KR20220007056A (ko) 2022-01-18
CA3136658A1 (en) 2020-10-15
SG11202111249YA (en) 2021-11-29
WO2020210655A1 (en) 2020-10-15
EP3953371A1 (en) 2022-02-16

Similar Documents

Publication Publication Date Title
JP2025106514A (ja) 脳内への特異性が増強されたウイルス組成物
JP7624724B2 (ja) 標的遺伝子療法のためのアデノ随伴ウイルス組成物
CN115023242B (zh) 腺相关病毒载体变体
CN110770346B (zh) 多倍体腺相关病毒载体及其制备和使用方法
CN113383010B (zh) 具有经工程化改造的启动子的共济蛋白表达构建体及其使用方法
AU2018365677C1 (en) Means and method for preparing viral vectors and uses of same
Zwi-Dantsis et al. Adeno-associated virus vectors: principles, practices, and prospects in gene therapy
JP2022101648A (ja) 一本鎖アデノ随伴ウイルス9または自己相補型アデノ随伴ウイルス9の脳脊髄液への注射
EP3044318B1 (en) Selective recovery
JP2024026105A (ja) 抗体回避ウイルスベクターのための方法および組成物
CN110520536A (zh) 用于穿过维管结构的基因转移的方法和组合物
JP2024513949A (ja) 脳内発現レベルが高いaav組成物
CN108699565A (zh) 用于定向腺相关病毒(aav)的靶向肽
KR20230034211A (ko) 변형된 아데노-관련 바이러스 5 캡시드 및 이의 용도
TW202449167A (zh) 用於治療肌肉萎縮性脊髓側索硬化症之組成物及方法
JP2023515795A (ja) Aavカプシド-プロモーター相互作用および細胞選択的遺伝子発現
US20250197456A1 (en) Novel aav capsids for targeting nervous system and uses thereof
RU2845941C1 (ru) Варианты аденоассоциированного вирусного вектора
Nandi et al. Revolutionizing Gene Therapy: An Explicative Review on Engineering Adeno-associated Virus Vectors
EP4117734A1 (en) Gene therapy of niemann-pick disease type c
HK40016209A (en) Selective recovery

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230323

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240325

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240624

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240925

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250411

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20250512